Lido Advisors
CADL icon

Lido Advisors’s Candel Therapeutics CADL Stock Holding History

Lido Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$295K Buy
60,257
+56
+0.1% +$305 ﹤0.01% 1572
2025
Q4 		$307K Hold
60,201
– – ﹤0.01% 1557
2025
Q3 		$307K Buy
+60,201
New +$348K ﹤0.01% 1478

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lido Advisors's CADL Position: Q1 2026 in Review

Lido Advisors increased its Candel Therapeutics (CADL) stake by 0.09% in Q1 2026, buying an estimated $305 and bringing the position to 60,257 shares worth $295K. The position accounts for ﹤0.01% of the portfolio, ranked #1572.

Lido Advisors first reported a position in CADL in Q3 2025 and has held it in 3 quarters since. The position peaked at $307K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Lido Advisors held 60,257 shares of Candel Therapeutics worth $295K as of Q1 2026.
  • Lido Advisors bought 56 Candel Therapeutics shares in Q1 2026, an estimated $305.
  • Candel Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1572 holding.
  • Lido Advisors first reported a position in Candel Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Lido Advisors's Candel Therapeutics position peaked at $307K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.